Pfizer Inc v. Ranbaxy Labs. Ltd. (Fed. Cir. 2006), available at 457 F.3d 1284

In one of the most economically significant patent cases of the last century, Seitz Ross partner C.J. Seitz served as part of the trial and appeal team that successfully sustained Pfizer’s basic patent and its term extension to preserve Pfizer’s exclusivity over Lipitor®.  The Court of Appeals for the Federal Circuit ruled that Lipitor® remained covered by Pfizer’s basic patent in the U.S. until 2010. This win secured Lipitor®’s status as the world’s best-selling drug.